Javier Larrauri
Autonomous University of Madrid
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Javier Larrauri.
Gastroenterology | 1998
Maria Guido; Massimo Rugge; Paloma Jara; Loreto Hierro; Raffaella Giacchino; Javier Larrauri; Lucia Zancan; Gioacchino Leandro; Carla E. Marino; Fiorella Balli; Alberto Bagni; Anna Timitilli; Flavia Bortolotti
BACKGROUND & AIMS Apart from the high-risk groups, the pathology of chronic hepatitis C in children is not well known. The aim of this study was to investigate the morphology of chronic hepatitis C in children without any underlying systemic disease and to evaluate its relationship to clinicovirological factors. METHODS Liver biopsy specimens from 80 children positive for antibody to hepatitis C virus were evaluated using a semiquantitative scoring system. RESULTS Chronic hepatitis was mild in most cases but had high-grade activity in 17 children (21.2%). A significant association was found between the grade of focal necrosis and alanine transaminase levels (P < 0.003). Fibrosis was absent in 22 cases (27.5%), mild in 44 (55%), and moderate in 13 (16.2%). Only 1 patient had cirrhosis. A significant relationship was detected between fibrosis scores and (1) duration of disease (P < 0.03); (2) portal inflammation (P < 0. 002); and (3) interface hepatitis (P < 0.003). CONCLUSIONS In otherwise healthy children, chronic hepatitis C is a morphologically mild disease in most cases. Fibrosis increases with the duration of disease, suggesting that end-stage disease may develop in young adulthood. Alanine transaminase levels correlate with intralobular focal necrosis but not with other lesions. In this respect, liver biopsy retains its importance in the management of chronic hepatitis C in children.
Pediatric Infectious Disease Journal | 2008
Paloma Jara; Loreto Hierro; Angela de la Vega; Carmen Diaz; Carmen Camarena; E. Frauca; Gema Muñoz-Bartolo; Ruth Díez-Dorado; Concepción Ladrón de Guevara; Javier Larrauri; Magdalena Rueda
Background: Interferon (IFN)-&agr;2b plus ribavirin is approved for treatment of hepatitis C in children; however, little is known about efficacy and tolerability of pegylated IFN (PEG-IFN)-&agr;2b in this population. The objective of this study was to test the efficacy and safety of PEG-IFN-&agr;2b plus ribavirin in children with chronic hepatitis C. Methods: Thirty children 3–16 years of age who had detectable hepatitis C virus (HCV) RNA for ≥3 years after exposure and elevated alanine aminotransferase values received PEG-IFN-&agr;2b 1.0 &mgr;g/kg/wk plus ribavirin 15 mg/kg/d for 24 weeks (genotype 2/3) or 48 weeks (genotype 1/4). The primary endpoint was sustained virologic response (SVR), defined as undetectable HCV RNA (<50 IU/mL) at week 24 of follow-up. Results: SVR was achieved in 50% of patients (3/3 genotype 3; 12/27 genotype 1/4). At week 12, 52% of patients were HCV RNA negative and 72% had a >2 log10 decrease in viral load, compared with baseline; 87% and 71% of these patients, respectively, attained an SVR. Therapy was discontinued in 3 patients as a result of adverse events. No patient required ribavirin dose reduction; PEG-IFN-&agr;2b dose was reduced in 23% of patients to manage neutropenia. Conclusions: Combination therapy with PEG-IFN-&agr;2b and ribavirin treatment was effective in children with chronic hepatitis C. Virologic status at week 12 identified future responders and nonresponders. PEG-IFN-&agr;2b and ribavirin were reasonably well tolerated, with no unexpected or permanent adverse effects. Further studies are needed to identify the optimum treatment regimen for this patient population.
The American Journal of Gastroenterology | 2003
Maria Guido; Flavia Bortolotti; Gioacchino Leandro; Paloma Jara; Loreto Hierro; Javier Larrauri; Cristiana Barbera; Raffaella Giacchino; Lucia Zancan; Fiorella Balli; Carlo Crivellaro; Emilio Cristina; Angela Pucci; Massimo Rugge
Abstract Objective The natural history of chronic hepatitis C acquired in infancy is not well understood. The progression of fibrosis was analyzed in untreated children with chronic hepatitis C virus infection and no other hepatotoxic cofactors. Methods A total of 112 pediatric patients (13 with paired liver biopsies) were considered. Fibrosis was assessed by METAVIR score (i.e., stage F1 to F4). The ratio between the stage of fibrosis (METAVIR units) and the presumed duration of infection represented the “estimated” rate of fibrosis progression per year. In patients with paired biopsies, the “observed” rate of fibrosis progression was defined as the difference between the stage of fibrosis in the two biopsies divided by the time interval between them. Results Both age of patients at biopsy and duration of infection correlated with stage of fibrosis (p Conclusions Chronic hepatitis C acquired in childhood is a progressive, slow-moving, fibrotic disease. Fibrosis progression inferred on the basis of linear mathematical models should be critically evaluated in the clinical practice.
The New England Journal of Medicine | 2009
Paloma Jara; Loreto Hierro; Pilar Martínez-Fernández; Rita Alvarez-Doforno; Francisca Yánez; M.C. Diaz; Carmen Camarena; Angela de la Vega; E. Frauca; Gema Muñoz-Bartolo; Manuel López-Santamaría; Javier Larrauri; Luis Alvarez
Severe bile salt export pump (BSEP) deficiency is a hereditary cholestatic condition that starts in infancy and leads to end-stage liver disease. Three children who underwent orthotopic liver transplantation for severe BSEP deficiency had post-transplantation episodes of cholestatic dysfunction that mimicked the original disease. Remission of all episodes was achieved by intensifying the immunosuppressive regimen. The phenotypic recurrence of the disease correlated with the presence of circulating high-titer antibodies against BSEP that inhibit transport by BSEP in vitro. When administered to rats, these antibodies targeted the bile canaliculi and impaired bile acid secretion.
Journal of Pediatric Gastroenterology and Nutrition | 1999
Icíar Sánchez-albisua; Teresa Garde; Loreto Hierro; Carmen Camarena; E. Frauca; Angela de la Vega; M.C. Diaz; Javier Larrauri; Paloma Jara
BACKGROUND To study the clinical features of Wilsons disease in childhood. METHODS Retrospective review of the clinical, laboratory, and histologic features and prognosis of Wilsons disease in 26 Spanish children. RESULTS The first medical visit, at age 9.8+/-3.4 years (range, 4-16 years), was prompted by liver dysfunction detected accidentally (61%), symptoms of liver disease (27%), family screening (8%), and extrapyramidal symptoms and personality changes (4%). There were laboratory data of hepatic failure in 27%. All copper metabolism test results (total serum copper, 24-hour urine excretion, serum ceruloplasmin) were abnormal in 62%, two in 27%, and one in 11%. All patients in whom extrahepatic involvement was found at diagnosis had severe liver disease. Histologic findings were portal fibrosis with steatosis (29%), cirrhosis (21%), portal fibrosis (17%), chronic active hepatitis (17%), and minimal changes or normality (17%). Penicillamine was administered to all but one patient. Four children underwent liver transplantation, three of them having received penicillamine for 12, 45, and 70 days. Three other patients recovered from liver failure after 1 year of treatment with penicillamine. After a follow-up of 4.5+/-3.3 years, all the children survived. Penicillamine caused severe toxicity in one patient. CONCLUSIONS Wilsons disease in childhood is generally detected by maintaining a high suspicion of liver disease in patients who have no or nonspecific hepatic symptoms. Kayser-Fleischer ring is rare in childhood. Drug therapy is effective and well tolerated, even in some cases of hepatic insufficiency.
Journal of Pediatric Gastroenterology and Nutrition | 1990
Gerardo Prieto; Isabel Polanco; J. Sarria; Javier Larrauri; Lassaletta L
The juvenile form is the usual type of colonic polyp seen during childhood. However, mixed forms associating juvenile and adenomatous polyps have been reported. A syndrome including the association of generalized juvenile polyposis, pulmonary arteriovenous malformation, and hypertrophic osteoarthropathy has been described in three cases; however, this is the first report of the association of mixed juvenile and adenomatous polyposis, pulmonary arteriovenous malformation, and hypertrophic osteoarthropathy.
Journal of Pediatric Gastroenterology and Nutrition | 2001
Mercedes Diaz; N. Leal; Pedro Olivares; Javier Larrauri; Juan A. Tovar
Esophagitis caused by herpes virus or Candida albicans infection may occur in patients with immune depression or cancer in whom the defense against these agents may be impaired, but it is rare in immunocompetent individuals. These infections seldom lead to complications, and they usually can be managed with antimycotic drugs. Esophageal strictures of these origins, like those of other causes, can be managed successfully by repeated dilatations in most patients, and esophageal replacement rarely is needed. We report two children with intractable esophageal strictures caused respectively by herpes virus and Candida infections who required esophageal replacement after failure of dilatations and medical treatment.
Human Molecular Genetics | 2004
Luis Alvarez; Paloma Jara; Elena Sánchez-Sabaté; Loreto Hierro; Javier Larrauri; M.C. Diaz; Carmen Camarena; Angela de la Vega; E. Frauca; Eduardo López-Collazo; Pablo Lapunzina
Hepatology | 1998
Carmelo García-Monzón; Paloma Jara; Miguel Fernández-Bermejo; Loreto Hierro; E. Frauca; C. Camarena; Carmen Diaz; Angela de la Vega; Javier Larrauri; Consuelo García-Iglesias; M.J. Borque; Paloma Sanz; Luisa García-Buey; José A. Moreno-Monteagudo; Ricardo Moreno-Otero
Transplantation Proceedings | 1997
Paloma Jara; Loreto Hierro; Maravillas Díaz; E. Frauca; C. Camarena; A de la Vega; Manuel Lopez Santamaria; J. Murcia; Javier Larrauri; C. Sanchez-Peinado; C. Prieto; M. Zafra; M. Gamez